Weaker tumor addiction to ER signaling coupled with co-occurring oncogenic drivers could in part explain the clinical observations that hormone receptor-positive YBCs respond more poorly to endocrine therapies than their older counterparts. This evidence concerns the gene NR4A1 and neoplasm.